Admission to AIM First day of trading Poolbeg Pharma (AIM: POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model , is pleased to announce that admission of its entire issued share capital to trading on the AIM market of the London Stock Exchange will become effective and dealings will commence at 8.00 a.m. today under the ticker POLB and with the ISIN GB00BKPG7Z60 ( Admission ). The full Admission Document is available to view on the Company s website at www.poolbegpharma.com · Shares priced at 10p per share equating to a market capitalisation at Admission of £50m
Investegate |Synairgen plc Announcements | Synairgen plc: Result of AGM
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Investegate |Poolbeg Pharma plc Announcements | Poolbeg Pharma plc: Intention to Float on AIM
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.